KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Account Payables (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Change in Account Payables data on record, last reported at -$10.8 million in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 275.35% year-over-year to -$10.8 million; the TTM value through Dec 2025 reached -$5.3 million, down 291.49%, while the annual FY2025 figure was -$5.3 million, 291.49% down from the prior year.
  • Change in Account Payables reached -$10.8 million in Q4 2025 per ACAD's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $5.2 million in Q4 2023 and bottomed at -$10.8 million in Q4 2025.
  • Average Change in Account Payables over 5 years is $120500.0, with a median of $818000.0 recorded in 2022.
  • Peak YoY movement for Change in Account Payables: skyrocketed 993.26% in 2022, then crashed 275.35% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$846000.0 in 2021, then soared by 423.64% to $2.7 million in 2022, then skyrocketed by 91.12% to $5.2 million in 2023, then crashed by 155.21% to -$2.9 million in 2024, then plummeted by 275.35% to -$10.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$10.8 million in Q4 2025, $1.6 million in Q3 2025, and $2.0 million in Q2 2025.